NEW YORK (GenomeWeb News) – Swiss proteomics firm Biognosys has raised CHF2.7 million ($3 million) in a Series A round, it announced on Monday.
Participants in the round include Hellmut Kirchner, the co-founder of venture fund Techno Venture Management; Redalpine Capital I, which led Biognosys' seed funding in 2009; ZKB, the venture arm of Cantonal Bank of Zurich; Syngenta Ventures; and private investors.
"With the completion of this Series A round, we are well capitalized to bring Biognosys to the next phase of growth," Oliver Rinner, the company's CEO, said in a statement. He did not provide further details about the use of the funds.
In connection with the funding, Biognosys also announced additions to its board including Kirchner, Ignacio Martinez, a principal in Syngenta Ventures, and Harry Welten, CFO of Cytos Biotechnology.
Biognosys was spun out of the Swiss Federal Institute of Technology in 2008 and provides targeted mass spectrometry-based services to companies operating in the diagnostics, pharma, healthcare, biotechnology, and agricultural spaces. Customers include Novartis, Pfizer, Integrated Diagnostics, and Philips, according to its website.